Hospira irinotecan hydrochloride trihydrate IV Infusion 40 mg

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

irinotecan hydrochloride trihydrate, Quantity: 20 mg/mL

Commercializzato da:

Hospira Australia Pty Ltd

INN (Nome Internazionale):

irinotecan hydrochloride trihydrate

Forma farmaceutica:

Injection, intravenous infusion

Composizione:

Excipient Ingredients: lactic acid; sorbitol; water for injections

Via di somministrazione:

Intravenous Infusion

Confezione:

1 x 5 mL vial

Classe:

Medicine Listed (Export Only)

Tipo di ricetta:

(S1) This Schedule is intentionally blank

Indicazioni terapeutiche:

Small cell lung carcinoma, non-small cell lung carcinoma, cervical carcinoma, ovarian cancer, stomach cancer (inoperable or recurrent), colorectal cancer (inoperable or recurrent), breast cancer (inoperable or recurrent), squamous cell carcinoma, malignant lymphoma (non Hodgkin's disease).

Dettagli prodotto:

Visual Identification: A clear, colourless to pale yellow solution; Container Type: Vial; Container Material: Glass Type I Coloured; Container Life Time: 36 Months; Container Temperature: Room temperature; Container Closure: Neither child resistant closure nor restricted flow insert

Stato dell'autorizzazione:

Listed (Export Only)

Data dell'autorizzazione:

2013-01-30